Lamivudine therapy of WHV-infected woodchucks

Virology

Volumn 245, Issue 1, 1998, Pages 18-32

  Mason, William S ^a   Cullen, John ^b   Moraleda, Gloria ^a   Saputelli, Jeffry ^a   Aldrich, Carol E ^a   Miller, Darren S ^c   Tennant, Bud ^d   Frick, Lloyd ^e   Averett, Devron ^e   Condreay, Lynn D ^e   Jilbert, Allison R ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d Cornell University ^*  (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; GAMMA GLUTAMYLTRANSFERASE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; ENZYME ACTIVE SITE; HEPATITIS VIRUS; LIVER BIOPSY; LIVER CANCER; LIVER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS HEPATITIS; WOODCHUCK;

ANIMALIA; DNA VIRUSES; HEPATITIS B VIRUS; MARMOTA MONAX; WOODCHUCK HEPATITIS B VIRUS;

EID: 0032565689     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9150     Document Type: Article

References (49)

1. Abe K., Kurata T., Shikata T., Tennant B. C. Enzyme-altered liver cell foci in woodchucks infected with woodchuck hepatitis virus. Jpn. J. Cancer Res. (Gann). 79:1988;466-472.
2. Aguesse-Germon S., Liu S.-H., Chevallier M., Pichoud C., Jamard C., Borel C., Chu C. K., Trepo C., Cheng Y.-C., Zoulim F. Inhibitory effect of 2′fluoro-5-methyl-B-L. Antimicrob. Agents Chemother. 42:1997;369-376.
3. Allen M. I., Deslauriers M., Andrews C. W., Tipples G. A., Walters K.-A., Tyrell D. L. J., Brown N., Condreay L. D. Identification and characterization of mutations in HBV resistant to lamivudine. Hepatology. 1997.
4. Averett D. R., Mason W. S. Evaluation of drugs for antiviral activity against hepatitis B virus. Viral Hepatitis Rev. 1:1995;129-142.
5. Bartenschlager R., Junker-Niepmann M., Schaller H. The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J. Virol. 64:1990;5324-5332.
6. Bartholomeusz A., Locarnini S. Mutations in the hepatitis B virus polymerase gene associated with antiviral drug resistance. Int. Antiviral News. 5:1997;123-124.
7. Bartholomew M. M., Jansen R. W., Jeffers L. J., Reddy K. R., Johnson L. C., Bunzendahl H., Condreay L. D., Tzakis A. G., Schiff E. R., Brown N. A. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 349:1997;20-22.
8. Cavanaugh V. J., Guidotti L., Chisari F. V. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 71:1997;3236-3243.
9. Chen H.-S., Kew M. C., Hornbuckle W. E., Tennant B. C., Cote P. J., Gerin J. L., Purcell R. H., Miller R. H. The precore gene of the woodchuck hepatitis virus genome is not essential for viral replication in the natural host. J. Virol. 66:1992;5682-5684.
10. Chisari F. V. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:1995;29-60.
11. Cohen J. I., Miller R. H., Rosenblum B., Denniston K., Gerin J. L., Purcell R. H. Sequence comparison of woodchuck hepatitis virus replicative forms shows conservation of the genome. Virology. 162:1988;12-20.
12. Dienstag J. L., Perrillo R. P., Schiff E. R., Bartholomew M., Vicary C., Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1995;1657-1661.
13. Evans A. A., O'Connell A. P., Pugh J. C., Mason W. S., Shen F.-M., Chen G.-C., Lin W.-Y., Dia A., M'Boup S., Drame B., London W. T. Early resolution of viremia may be associated with a reduced risk of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev. 1997.
14. Finzi D., Hermankova M., Pierson T., Carruth L. M., Buck C., Chaisson R. E., Quinn T. C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D. D., Richman D. D., Siliciano R. F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1997;1295-1300.
15. Fischer K. P., Tyrrell D. L. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [( - )-beta-L-2′,3′-dideoxy-3′-thiacytidine] in vitro. Antimicrob. Agents Chemother. 40:1996;1957-1960.
16. Fourel I., Cullen J. M., Saputelli J., Aldrich C. E., Schaffer P., Averett D., Pugh J., Mason W. S. Evidence that hepatocyte turnover is required for rapid clearance of DHBV during antiviral therapy of chronically infected ducks. J. Virol. 68:1994;8321-8330.
17. Frick L. W., St. John L., Taylor L. C., Painter G. R., Furman P. A., Liotta D. C., Furfine E. S., Nelson D. J. Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. Antimicrob. Agents Chemother. 37:1993;2285-2292.
18. Frick L. W., Lambe C. U., St. John J. L., Taylor L. C., Nelson D. J. Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2′R,5′S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. Antimicrob. Agents Chemother. 38:1994;2722-2729.
19. Gerin J. L., Cote P. J., Korba B. E., Tennant B. C. Cancer Detect Prevent. 14:1989;227-229.
20. Guidotti L. G., Borrow P., Hobbs M. V., Matzke B., Gresser I., Oldstone M. B., Chisari F. V. Viral cross talk: Intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc. Natl. Acad. Sci. USA. 93:1996a;4589-4594.
21. Guidotti L. G., Ishikawa T., Hobbs M. V., Matzke B., Schreiber R., Chisari F. V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 4:1996b;25-36.
22. Hirsch R. C., Loeb D. D., Pollack J. R., Ganem D. Cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA. J. Virol. 65:1991;3309-3316.
23. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
24. Honkoop P., De Man R. A., Scholte H. R., Zondervan P. E., Van Den Berg J. W. O., Rademakers H. P., Schalm S. W. Effect of lamivudine on the morphology and function of mitochondria in patients with chronic hepatitis B. Hepatology. 26:1997;211-215.
25. Hoofnagle J. H., DiBisceglie A. M. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:1997;347-356.
26. Innaimo S. F., Seifer M., Bisacchi G. S., Standring D. N., Zahler R., Colonno R. J. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 7:1997;1444-1448.
27. Jilbert A. R., Wu T.-T., England J. M., de la M. Hall P., Carp N. Z., O'Connell A. P., Mason W. S. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J. Virol. 66:1992;1377-1388.
28. Kajino K., Jilbert A. R., Saputelli J., Aldrich C. E., Cullen J., Mason W. S. Woodchuck hepatitis virus infections: Very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J. Virol. 68:1994;5792-5803.
29. Kodama K., Ogasawara N., Yoshikawa H., Murakami S. Nucleotide sequence of a cloned woodchuck hepatitis virus genome: Evolutional relationship between hepadnaviruses. J. Virol. 56:1985;978-986.
30. Korba B., Wells F. V., Baldwin B., Cote P. J., Tennant B. C., Popper H., Gerin J. L. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: Presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology. 9:1989;461-470.
31. Ling R., Mutimer D., Ahmed M., Boxall E. H., Elias E., Dusheiko G. M., Harrison T. J. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
32. Luscombe C., Pedersen J., Uren E., Locarnini S. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: Effect on intrahepatic-viral DNA, RNA, and protein expression. Hepatology. 24:1996;766-773.
33. Mancini M., Hadchouel M., Davis H. L., Whalen R. G., Tiollais P., Michel M. L. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc. Natl. Acad. Sci. USA. 93:1996;12496-12501.
34. Mason W. S., Aldrich C., Summers J., Taylor J. M. Asymmetric replication of duck hepatitis B virus in liver cells: Free minus-strand DNA. Proc. Natl. Acad. Sci. USA. 79:1982;3997-4001.
35. Miller R. H., Girones R., Cote P. J., Hornbuckle W. E., Chestnut T., Baldwin B. H., Korba B. E., Tennant B. C., Gerin J. L., Purcell R. H. Evidence against a requisite role for defective virus in the establishment of persistent hepadnavirus infections. Proc. Natl. Acad. Sci. USA. 87:1990;9329-9332.
36. Moraleda G., Saputelli J., Aldrich C. E., Averett D., Condreay L., Mason W. S. Lack of effect of antiviral therapy in nondividing heptocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J. Virol. 71:1997;9392-9399.
37. Newbold J. E., Xin H., Tencza M., Sherman G., Dean J., Bowden S., Locarnini S. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J. Virol. 69:1995;3350-3357.
38. Nowak M. A., Bonhoeffer S., Hill A. M., Boehme R., Thomas H. C., McDade H. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA. 93:1996;4398-4402.
39. Perrillo R. P., Schiff E. R., Davis G. L., Bodenheimer H. C., Lindsay K., Payne J., Dienstag J. L., O'Brein C., Tamburro C., Jacobson I. M., Sampliner R., Feit D., Lefkowitch J., Kuhns M., Meschievitz C., Sanghvi B., Albrecht J., Gibas A. A randomized, controlled trial of interferon α-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med. 323:1990;295-301.
40. Popper H., Roth L., Purcell R. H., Tennant B. C., Gerin J. L. Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc. Natl. Acad. Sci. USA. 84:1987;866-870.
41. Schinazi R. F., Hough L., Juodawlkis A., Marion P., Tennant B. Comparative activation of 2′-deoxycytidine and antiviral oxathiolane cytosine nucleosides by different mammalian liver extracts. Antiviral Res. 34:1997;A65.
42. Summers J., Mason W. S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell. 29:1982;403-415.
43. Tencza M. G., Newbold J. E. Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: Drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles. J. Med. Virol. 51:1997;6-16.
44. Tennant B. C., Baldwin B. H., Hornbuckle W. E., Korba B. E., Cote P. J., Gerin J. L. Animal models in the preclinical assessment of therapy for viral hepatitis. Antiviral Ther. 1:1997;47-52.
45. Tipples G. A., Ma M. M., Fischer K. P., Bain V. G., Kneteman N. M., Tyrrell D. L. J. Mutation in HBV DNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
46. Tuttleman J., Pourcel C., Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells. Cell. 47:1986;451-460.
47. Tyrrell D. L. J., Mitchell M. C., de Man R. A., Schalm S. W., Main J., Thomas H. C., Fevery J., Nevens F., Beranek P., Vicary C. Phase II trial of lamivudine for chronic hepatitis B. Hepatology. 18:1994;112a.
48. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H., Saag M. S., Shaw G. M. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.
49. Wong J. K., Hezareh M., Gunthard H. F., Havlir D. V., Ignacio C. C., Spina C. A., Richman D. D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1997;1291-1295.